Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, in Subjects with Overweight or Obesity-A 48-Week, Placebo-Controlled, Phase 2 (MOMENTUM) Trial

被引：1
|
作者：
Aronne, Louis
Harris, M. Scott
Roberts, M. S.
Suschak, John J.
Tomah, Shaheen
Kasper, Jonathan
He, Liang
Yang, Jay
Frias, Juan P.
Browne, Sarah K.
机构：
来源：
DIABETES | 2024年 / 73卷
关键词：
D O I：
10.2337/db24-262-OR
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
262-OR
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Results of the 48-Week Blinded Extension of RADIANCE: a Randomized, Placebo-controlled Phase 2 Trial of Oral Ozanimod in Relapsing Multiple Sclerosis
    Cohen, Jeffrey A.
    Selmaj, Krzysztof
    Arnold, Douglas
    Comi, Giancarlo C.
    Bar-Or, Amit
    Gujrathi, Sheila
    Hartung, Jeffrey P.
    Olson, Allan
    Cravets, Matt
    Frohna, Paul A.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 72 - 72
  • [22] ZT002, a novel ultra long-acting GLP-1 receptor agonist in adults with overweight or obesity: a randomised, placebo-controlled, multiple ascending dose phase 1c study
    Ji, L.
    Zhou, H.
    Li, X.
    Xu, X.
    Wong, A.
    Zu, Y.
    Song, X.
    Zhang, Y.
    Lin, S.
    Zhang, X.
    Zhang, Y.
    DIABETOLOGIA, 2024, 67 : S81 - S81
  • [23] A phase 2, randomized, double-blind, placebo-controlled, 48-Week study of the efficacy and safety of losmapimod in subjects with FSHD: ReDUX4
    Tawil, R.
    Wagner, K.
    NEUROMUSCULAR DISORDERS, 2021, 31 : S48 - S49
  • [24] Safety and efficacy of GLP-1 and glucagon receptor dual agonist for the treatment of type 2 diabetes and obesity: a systematic review and meta-analysis of randomized controlled trials
    Deng, Bixin
    Ruan, Tiechao
    Lu, Wenting
    Ying, Junjie
    Li, Shiping
    Zhou, Ruixi
    Mu, Dezhi
    ENDOCRINE, 2024, 86 (01) : 15 - 27
  • [25] Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial
    Ishoy, Pelle L.
    Knop, Filip K.
    Broberg, Brian V.
    Bak, Nikolaj
    Andersen, Ulrik B.
    Jorgensen, Niklas R.
    Holst, Jens J.
    Glenthoj, Birte Y.
    Ebdrup, Bjorn H.
    DIABETES OBESITY & METABOLISM, 2017, 19 (02): : 162 - 171
  • [26] Survodutide, a glucagon receptor/glucagon-like peptide-1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo-controlled, dose-finding, phase 2 trial
    le Roux, Carel W.
    Steen, Oren
    Lucas, Kathryn J.
    Ekinci, Elif I.
    Startseva, Elena
    Unseld, Anna
    Hussain, Samina Ajaz
    Hennige, Anita M.
    DIABETES OBESITY & METABOLISM, 2024,
  • [27] MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
    Ambery, Philip
    Parker, Victoria E.
    Stumvoll, Michael
    Posch, Maximilian G.
    Heise, Tim
    Plum-Moerschel, Leona
    Tsai, Lan-Feng
    Robertson, Darren
    Jain, Meena
    Petrone, Marcella
    Rondinone, Cristina
    Hirshberg, Boaz
    Jermutus, Lutz
    LANCET, 2018, 391 (10140): : 2607 - 2618
  • [28] Pharmacological characterisation of MED10382, a glucagon/GLP-1 dual agonist for treatment of obesity and type 2 diabetes
    Rossi, A.
    Naylor, J.
    Will, S.
    Bhagroo, N.
    Bednarek, M. A.
    Coghlan, M. P.
    Konkar, A.
    Hornigold, D. C.
    DIABETOLOGIA, 2016, 59 : S58 - S58
  • [29] Pharmacokinetics and pharmacodynamics of rituximab in adults with Relapsing Remitting Multiple Sclerosis (RRMS) in a 48-week phase 90 placebo-controlled, multicenter trial
    Bar-Or, Amit
    Waubant, Emmanuelle
    Ren, Song
    Sarkar, Neena
    Smith, Craig
    NEUROLOGY, 2008, 70 (11) : A226 - A227
  • [30] Plasma lipidomic profiling of subjects with overweight or obesity following treatment with the glucagon-like peptide 1/glucagon dual receptor agonist pemvidutide: an investigation of lipid signatures associated with metabolic dysfunction-associated steatohepatitis
    Suschak, John
    Georges, Bertrand
    Browne, Sarah
    Alonso, Cristina
    Roberts, M. Scot
    Harris, M. Scott
    JOURNAL OF HEPATOLOGY, 2024, 80 : S529 - S529
12345